157 related articles for article (PubMed ID: 37428871)
1. In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice.
Li BE; Li GY; Cai W; Zhu Q; Seruggia D; Fujiwara Y; Vakoc CR; Orkin SH
Blood Adv; 2023 Sep; 7(18):5281-5293. PubMed ID: 37428871
[TBL] [Abstract][Full Text] [Related]
2. Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells.
Shi X; Kitano A; Jiang Y; Luu V; Hoegenauer KA; Nakada D
Exp Hematol; 2018 Aug; 64():33-44.e5. PubMed ID: 29751067
[TBL] [Abstract][Full Text] [Related]
3. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia.
Tothova Z; Krill-Burger JM; Popova KD; Landers CC; Sievers QL; Yudovich D; Belizaire R; Aster JC; Morgan EA; Tsherniak A; Ebert BL
Cell Stem Cell; 2017 Oct; 21(4):547-555.e8. PubMed ID: 28985529
[TBL] [Abstract][Full Text] [Related]
4. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
[TBL] [Abstract][Full Text] [Related]
5. MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.
Yamashita N; Morimoto Y; Fushimi A; Ahmad R; Bhattacharya A; Daimon T; Haratake N; Inoue Y; Ishikawa S; Yamamoto M; Hata T; Akiyoshi S; Hu Q; Liu T; Withers H; Liu S; Shapiro GI; Yoshizumi T; Long MD; Kufe D
Mol Cancer Res; 2023 Mar; 21(3):274-289. PubMed ID: 36445328
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease.
Sano S; Oshima K; Wang Y; Katanasaka Y; Sano M; Walsh K
Circ Res; 2018 Jul; 123(3):335-341. PubMed ID: 29728415
[TBL] [Abstract][Full Text] [Related]
7. Single-cell resolution reveals RalA GTPase expanding hematopoietic stem cells and facilitating of BCR-ABL1-driven leukemogenesis in a CRISPR/Cas9 gene editing mouse model.
Yin Z; Su R; Ge L; Wang X; Yang J; Huang G; Li C; Liu Y; Zhang K; Deng L; Fei J
Int J Biol Sci; 2023; 19(4):1211-1227. PubMed ID: 36923939
[TBL] [Abstract][Full Text] [Related]
8. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
[TBL] [Abstract][Full Text] [Related]
9. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets.
Wang T; Pine AR; Kotini AG; Yuan H; Zamparo L; Starczynowski DT; Leslie C; Papapetrou EP
Cell Stem Cell; 2021 Jun; 28(6):1074-1089.e7. PubMed ID: 33571445
[TBL] [Abstract][Full Text] [Related]
10. Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma.
Schoenfeld DA; Zhou R; Zairis S; Su W; Steinbach N; Mathur D; Bansal A; Zachem AL; Tavarez B; Hasson D; Bernstein E; Rabadan R; Parsons R
Mol Cancer Res; 2022 Aug; 20(8):1193-1207. PubMed ID: 35412614
[TBL] [Abstract][Full Text] [Related]
11. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
Liu XD; Kong W; Peterson CB; McGrail DJ; Hoang A; Zhang X; Lam T; Pilie PG; Zhu H; Beckermann KE; Haake SM; Isgandrova S; Martinez-Moczygemba M; Sahni N; Tannir NM; Lin SY; Rathmell WK; Jonasch E
Nat Commun; 2020 May; 11(1):2135. PubMed ID: 32358509
[TBL] [Abstract][Full Text] [Related]
12. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.
Gundry MC; Brunetti L; Lin A; Mayle AE; Kitano A; Wagner D; Hsu JI; Hoegenauer KA; Rooney CM; Goodell MA; Nakada D
Cell Rep; 2016 Oct; 17(5):1453-1461. PubMed ID: 27783956
[TBL] [Abstract][Full Text] [Related]
13. Mouse Models of Myeloid Malignancies.
Basheer F; Vassiliou G
Cold Spring Harb Perspect Med; 2021 Jan; 11(1):. PubMed ID: 32071146
[TBL] [Abstract][Full Text] [Related]
14. PBRM1 bromodomains variably influence nucleosome interactions and cellular function.
Slaughter MJ; Shanle EK; McFadden AW; Hollis ES; Suttle LE; Strahl BD; Davis IJ
J Biol Chem; 2018 Aug; 293(35):13592-13603. PubMed ID: 29986887
[TBL] [Abstract][Full Text] [Related]
15. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia.
Vuelta E; Ordoñez JL; Alonso-Pérez V; Méndez L; Hernández-Carabias P; Saldaña R; Sevilla J; Sebastián E; Muntión S; Sánchez-Guijo F; Hernández-Rivas JM; García-Tuñón I; Sánchez-Martín M
CRISPR J; 2021 Aug; 4(4):519-535. PubMed ID: 34406033
[TBL] [Abstract][Full Text] [Related]
17. Transcription control by the ENL YEATS domain in acute leukaemia.
Erb MA; Scott TG; Li BE; Xie H; Paulk J; Seo HS; Souza A; Roberts JM; Dastjerdi S; Buckley DL; Sanjana NE; Shalem O; Nabet B; Zeid R; Offei-Addo NK; Dhe-Paganon S; Zhang F; Orkin SH; Winter GE; Bradner JE
Nature; 2017 Mar; 543(7644):270-274. PubMed ID: 28241139
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
Gao W; Li W; Xiao T; Liu XS; Kaelin WG
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
[TBL] [Abstract][Full Text] [Related]
20. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.
Pan D; Kobayashi A; Jiang P; Ferrari de Andrade L; Tay RE; Luoma AM; Tsoucas D; Qiu X; Lim K; Rao P; Long HW; Yuan GC; Doench J; Brown M; Liu XS; Wucherpfennig KW
Science; 2018 Feb; 359(6377):770-775. PubMed ID: 29301958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
